This article provides general scientific information regarding standard laboratory in vitro and in vivo research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.
Monotherapy with MOUNJARO 5 mg, 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see Table 4)
5 Importantly, although the glucose-lowering effects of SGLT2 inhibitors reduce with decreasing renal function, the benefits on renal and cardiovascular disease are maintained
There was no plateau, and in fact it appears longer term trials will probably easily clear 20% weight loss, especially if metformin and/or SGLT2i medications are added on as these can both add another 2-3% extra weight loss when combined with a GLP-1 medication
Once you stop taking tirzepatide, its beneficial effects on appetite and metabolism decrease
For the deep dives, see What Is CagriSema